<DOC>
	<DOC>NCT02326376</DOC>
	<brief_summary>A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.</brief_summary>
	<brief_title>Kineret CAPS Post Authorisation Study</brief_title>
	<detailed_description />
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Informed consent by the patient and/or caregiver Kineret treatment will be according to the Summary of Product Characteristics (SmPC), as confirmed by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>